Figure 1.

Treatment protocol of the BELONG study. AZT, azathioprene; CYC, cyclophosphamide; EL, EUROLUPUS; LN, lupus nephritis; MMF, mycophenolate mofetil; OCR, ocrelizumab; ORR, overall renal response; PBO, placebo.

Reddy et al. Arthritis Research & Therapy 2013 15(Suppl 1):S2   doi:10.1186/ar3910